Prostate cancer is the most common malignancy and the second leading cause of cancer-related deaths among men in western countries. Prostate cancer may result in small, harmless tumors with no symptoms or develop into to a more aggressive cancer. Therefore, diagnosis of prostate cancer is accompanied with great challenges, i.e. to reduce the mortality but only treat when is necessary. Today, the major problem of prostate cancer diagnostics is the over-diagnosis due to the unspecific test, based on Prostate-Specific Antigen (PSA). Hence, there are urgent needs for additional robust and clinical relevant biomarkers that can improve risk classification among men with modestly elevated PSA, using a non-invasive diagnostic test.
Solution provided by Immunovia
Based on IMMray™ technology, Immunovia has initiated a discovery study in collaboration with CREATE Health Translational Cancer Center at Lund University. The aim is to provide a blood-based test for risk-group classification, providing clinicians with actionable information. CREATE Health has, in an initial pilot-study, defined a condensed set of plasma biomarkers (a biomarker signature) associated with prostate cancer. The biomarker signature will be further refined to allow classification of men with modestly elevated PSA that are (i) healthy and therefore can avoid biopsy and (ii) men that need a biopsy to be correctly diagnosed.